Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joachim Grevel

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|February 12, 2024
Application of multistate modeling to clinical data analysisJoachim Grevel, Joshua Veasy, Blesson Chacko
European Journal of Drug Metabolism and Pharmacokinetics|January 13, 2017
Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia PatientsRoberta Bursi, Chiara Piana, Joachim Grevel, et al.
Clinical Pharmacokinetics|June 4, 2021
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection FractionHauke Ruehs, Dagmar Klein, Matthias Frei, et al.
Clinical and Translational Science|March 29, 2019
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid CancerJoachim Grevel, Garrit Jentsch, Rupert Austin, et al.
European Journal of Endocrinology|June 12, 2023
Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 studyIsabella Gashaw, Stefanie Reif, Herbert Wiesinger, et al.
Hepatology International|December 3, 2016
HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinomaShi-Ming Lin, Sheng-Nan Lu, Ping-Tsung Chen, et al.
Molecular Cancer Therapeutics|October 18, 2019
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid TumorsFranck Morschhauser, Jean-Pascal Machiels, Gilles Salles, et al.
The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|February 12, 2024
Application of multistate modeling to clinical data analysisJoachim Grevel, Joshua Veasy, Blesson Chacko
European Journal of Drug Metabolism and Pharmacokinetics|January 13, 2017
Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia PatientsRoberta Bursi, Chiara Piana, Joachim Grevel, et al.
Clinical Pharmacokinetics|June 4, 2021
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection FractionHauke Ruehs, Dagmar Klein, Matthias Frei, et al.
Clinical and Translational Science|March 29, 2019
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid CancerJoachim Grevel, Garrit Jentsch, Rupert Austin, et al.
European Journal of Endocrinology|June 12, 2023
Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 studyIsabella Gashaw, Stefanie Reif, Herbert Wiesinger, et al.
Hepatology International|December 3, 2016
HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinomaShi-Ming Lin, Sheng-Nan Lu, Ping-Tsung Chen, et al.
Molecular Cancer Therapeutics|October 18, 2019
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid TumorsFranck Morschhauser, Jean-Pascal Machiels, Gilles Salles, et al.
The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
Pageof 1